WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015031228) ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/031228    International Application No.:    PCT/US2014/052451
Publication Date: 05.03.2015 International Filing Date: 25.08.2014
IPC:
A01N 43/40 (2006.01)
Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065-0907 (US).
MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road Hoddesdon Hertfordshire EN11 9BU (GB).
COOPER, Vincent, Brett [GB/GB]; (GB) (US only).
BRADLEY, Kathryn, Alanna [GB/GB]; (GB) (US only).
PYGALL, Samuel, Robert [GB/GB]; (GB) (US only).
GUPTA, Rajan [US/US]; (US) (US only).
STANFORD, Madison, Paige [US/US]; (US) (US only).
XIE, Lin [US/US]; (US) (US only)
Inventors: COOPER, Vincent, Brett; (GB).
BRADLEY, Kathryn, Alanna; (GB).
PYGALL, Samuel, Robert; (GB).
GUPTA, Rajan; (US).
STANFORD, Madison, Paige; (US).
XIE, Lin; (US)
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, NJ 07065-0907 (US)
Priority Data:
61/871,951 30.08.2013 US
Title (EN) ORAL PHARMACEUTICAL FORMULATION OF OMARIGLIPTIN
(FR) FORMULATION PHARMACEUTIQUE ORALE D'OMARIGLIPTINE
Abstract: front page image
(EN)The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non- reducible sugar diluents.
(FR)La présente invention concerne des formulations pharmaceutiques orales stables contenant des inhibiteurs de la dipeptidyl peptidase-4, tels que l'omarigliptine. Ces compositions pharmaceutiques comprennent de l'omarigliptine; et des excipients neutres, l'excipient neutre étant présent à environ 75% en poids de la formulation pharmaceutiques et comprenant au moins un diluant de sucre non réductible ou un mélange de diluants de sucre non réductibles.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)